{"id":"NCT01962207","sponsor":"Pfizer","briefTitle":"The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination","officialTitle":"A PHASE IIIB, OPEN, MULTI-CENTER STUDY TO EVALUATE THE LONG-TERM ANTIBODY PERSISTENCE AT 6, 7, 8, 9 AND 10 YEARS AFTER THE ADMINISTRATION OF ONE DOSE OF THE MENINGOCOCCAL CONJUGATE VACCINE MENACWY-TT VERSUS ONE DOSE OF MENINGITEC(REGISTERED) VACCINE OR ONE DOSE OF THE MENINGOCOCCAL POLYSACCHARIDE VACCINE MENCEVAX(REGISTERED) ACWY, AND TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A BOOSTER DOSE OF MENACWY-TT VACCINE ADMINISTERED 10 YEARS AFTER PRIMARY VACCINATION OF 1-10 YEAR OLD SUBJECTS WITH MENACWY-TT, MENINGITEC(REGISTERED) OR MENCEVAX(REGISTERED) ACWY.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10","primaryCompletion":"2017-12","completion":"2018-06","firstPosted":"2013-10-14","resultsPosted":"2019-06-07","lastUpdate":"2019-06-07"},"enrollment":243,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Meningococcal"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal vaccine GSK134612","otherNames":[]}],"arms":[{"label":"ACWY<2 Group","type":"EXPERIMENTAL"},{"label":"ACWY≥2 Group","type":"EXPERIMENTAL"},{"label":"MenCCRM Group","type":"EXPERIMENTAL"},{"label":"MenPS Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term antibody persistence 6, 7, 8, 9 and 10 years after receiving a primary vaccination of meningococcal conjugate vaccine MenACWY-TT versus Meningitec™ or Mencevax™ ACWY, and the safety and immunogenicity of a booster dose of MenACWY-TT administered 10 years after the primary vaccination. All subjects received a primary vaccination at 1 to 10 years of age in study 108658 (NCT00427908). No new subjects will be enrolled in this booster study.","primaryOutcome":{"measure":"Persistence Phase: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titers >=1:8 and >=1:128 For Each of the 4 Serogroups After 6 Years of Primary Vaccination","timeFrame":"6 years after primary vaccination (Year 1 of study MENACWY-TT-100)","effectByArm":[{"arm":"MenACWY-TT Vaccine: Less Than (<) 2 Years","deltaMin":51.9,"sd":null},{"arm":"MenCCRM (Meningitec) Vaccine: Less Than 2 Years","deltaMin":18.8,"sd":null},{"arm":"MenACWY-TT Vaccine: Greater Than or Equal to (>=) 2 Years","deltaMin":79.6,"sd":null},{"arm":"MenPS (Mencevax ACWY) Vaccine: Less Than 2 Years","deltaMin":12.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":9,"countries":["Finland"]},"refs":{"pmids":["32598244"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=MENACWY-TT-100&StudyName=A%20Phase%20Iiib%2C%20Open%2C%20Multi-center%20Study%20To%20Evaluate%20The%20Long-term%20Antibody%20Persistence%20At%206%2C%207%2C%208%2C%209%20And%2010%20Years%20After%20The%20Administration%20Of%20One%20Dose%20Of%20The%20Meningococcal%20Conjugate%20Vaccine%20Menacwy-tt%20Versus%20One%20Dose%20Of%20Meningitec%28registered%29%20Vaccine%20Or%20One%20Dose%20Of%20The%20Meningococcal%20Polysaccharide%20Vaccine%20Mencevax%28registered%29%20Acwy%2C%20And%20To%20Evaluate%20The%20Safety%20And%20Immunogenicity%20Of%20A%20Booster%20Dose%20Of%20Menacwy-tt%20Vaccine%20Administered%2010%20Years%20After%20Primary%20Vaccination%20Of%201-10%20Year%20Old%20Subjects%20With%20Menacwy-tt%2C%20Meningitec%28registered%29%20Or%20Mencevax%28registered%29%20Acwy."]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":76},"commonTop":["Injection site pain (pain at injection site)","Injection site erythema (redness)","Fatigue 1","Headache 1","Injection site swelling (swelling)"]}}